The Marfan syndrome (MFS) is a connective tissue disorder inherited as an autosomal dominant trait and caused by mutations in the gene encoding fibrillin, a 350-kD glycoprotein that multimerizes to form extracellular microfibrils. It has been unclear whether disease results from a relative deficiency of wild-type fibrillin; from a dominant-negative effect, in which mutant fibrillin monomers disrupt the function of the wild-type protein encoded by the normal allele; or from a dynamic and variable interplay between these two pathogenetic mechanisms. We have now addressed this issue in a cell culture system. A mutant fibrillin allele from a patient with severe MFS was expressed in normal human and murine fibroblasts by stable transfection. Immunohistochemical analysis of the resultant cell lines revealed markedly diminished fibrillin deposition and disorganized microfibrillar architecture. Pulse-chase studies demonstrated normal levels of fibrillin synthesis but substantially reduced deposition into the extracellular matrix. These data illustrate that expression of a mutant fibrillin allele, on a background of two normal alleles, is sufficient to disrupt normal microfibrillar assembly and reproduce the MFS cellular phenotype. This underscores the importance of the fibrillin amino-terminus in normal microfibrillar assembly and suggests that expression of the human extreme 5' fibrillin coding sequence may be sufficient, in isolation, to produce an animal model of MFS. Lastly, this substantiation of a dominant-negative effect offers mutant allele […] Clin. Invest. 1995. 95:874-880.)
Introduction
The Marfan Syndrome (MFS)' is a systemic disorder of connective tissue with autosomal dominant inheritance and a preva-lence of about 1 in 10,000 individuals. Hallmark features of the disease include ocular impairment, principally lens dislocation and myopia; skeletal abnormalities such as dolichostenomelia and joint laxity; and, most significantly, cardiovascular pathology, including aortic root dilatation and dissection, mitral valve prolapse, and mitral and aortic valvular insufficiency (1) (2) (3) . Positional cloning and candidate gene analyses recently culminated with the identification of FBN1, the gene encoding fibrillin, as the site of most, if not all, MFS-producing mutations (4) (5) (6) .
Fibrillin is a 350-kD glycoprotein and the principal component of the extracellular microfibril (7) . It is abundantly expressed in many tissues altered in the Marfan phenotype, including the skin, vascular wall, cartilage, suspensory ligament of the lens, and alveolar wall (8) . The structure of the protein is complex and redundant. It is comprised of 46 EGF-like motifs which are tandemly repeated and irregularly interspersed with TGF-,f1 binding protein (TGF-,31 bp)-like domains. A number of apparently unique cysteine-rich repeats are also present (9, 10). The abundance of cysteine-rich EGF-like and TGF-,31 bplike domains enables fibrillin monomers to participate in intramolecular as well as intermolecular interactions. Indeed, upon secretion into the extracellular matrix, fibrillin monomers rapidly form disulfide-bonded aggregates, which, in conjunction with other matrix components, lead to the formation of mature microfibrils (11, 12) . Rotary shadowing of these multimeric units reveals a beaded-string appearance, and it has been proposed that fibrillin monomers arrange in a head-to-tail fashion (8, 13) . Mature microfibrils have an average diameter of 10 nm, and the "beads" have been shown to be spaced at regular intervals of 26 to 60 nm (14) .
Several lines of evidence suggest that MFS follows a dominant-negative mechanism of pathogenesis. The disorder is inherited in an autosomal dominant fashion and is caused by mutations in a gene encoding a protein known to multimerize. In addition, a hallmark feature of classic MFS is severe deficiency of extracellular fibrillin, far below the amount predicted by a single functioning FBN1 allele ( 15, 16) . Finally, mutations causing very reduced levels of FBN1 mutant transcript have been associated with an extremely mild disease phenotype ( 17) . A dominant-negative scenario would thus involve mutant fibrillin monomers disrupting normal fibrillin multimer formation and consequently producing disease.
At the cellular level, fibroblasts cultured from MFS patients have been shown to exhibit consistent and relatively specific abnormalities by immunohistochemical and pulse-chase analyses. Indirect immunofluorescence of normal human fibroblasts with monoclonal antibodies to fibrillin results in a highly reproducible and distinct staining pattern. An abundant, organized F5UT-1S:  5'-GCA AGA GGC GGC GGG AG -3'   FB1S:  5'-GGA TTT ACC GTG CTT TTA GC-3'   FBICS:  5'-AAC GTG AAG GAA ACC AGA G -3'  FBIAS:   5'-TTC TGG CAT AGA CAG TGA TC-3'   FB2AS:   5'-GGC CTG GCA TTC ATC CAC-3'  MElS-lA:  5'-ACG AGC CAT GGG GCG GAC-3'  ME1S-B:  5'-CGG ACG CCA ATT TGG AGG C-3'  MElS-C:  5'-CGG GCC AAG AGA AGA GGC-3'  ME3AS-A  5'-CTG GAG CCA CAG GAA GGA G-3'  ME3AS-B  5'-CAA GTG CAC ATA TTT GGC CTC-3'  SP6: 5'-ATT TAG GTG ACA CTA TAG-3' T7:
5'-ATT ACG ACT CAC TAT AG-3' (20 mM Hepes, 150 mM NaCl, pH 7.4) in a sterile tube. 15 jig of Qiagen-extracted plasmid DNA were added, and the solutions were mixed and allowed to incubate for 10 min at room temperature. 10 ml of cell culture medium (composition as above) were then added to the transfection reagent-DNA mixture. The medium was aspirated from the fibroblast culture dishes, replaced with this 10 ml of transfection solution, and incubated at 37°C with 5% CO2 for 18 h. Parallel transfections of pDEL2 (experimental) and pcDNA3 (control) were performed, and resultant cells from the experimental and control transfections were carried through all subsequent stages of antibiotic selection and phenotype analysis.
Clonal selection of transfected cells. The transfection solution was removed and replaced with fresh cell culture medium containing -35 pg/ml active neomycin (Genticin; GIBCO BRL). To remove dead and dying cells, cultures were rinsed daily with Hank's balanced salt solution (GIBCO BRL) and overlaid with fresh neomycin-containing culture medium. After 2 wk, isolated clonal colonies of 10-100 cells could be observed. At this point the dishes were rinsed in Hank's balanced salt solution, and sterile 8 X 8 mm cloning cylinders (Specialty Media, Lavallette, NJ) were used to isolate individual clonal colonies. After treatment with trypsin, the cells were harvested and transferred to single wells of a 24-well sterile tissue culture plate (Falcon; Becton Dickinson, Franklin Lakes, NJ). Upon confluence, these clonal cultures were then plated in 75-cm2 tissue culture flasks (Coming) and maintained in neomycin-containing medium.
Southern blotting. Cultures carrying the transfected mini-gene were identified by Southern blot analysis of cellular genomic DNA by previously described methods (19) . Genomic DNA digests with EcoRI and Bsu36I (Boehringer Manheim) were performed, and the 0.44-kb HindIII-XbaI fragment of pDEL2 was 32P-labeled and used as a probe.
Transcript detection. Cultures expressing the transfected mini-gene were identified by RT-PCR analysis of cellular RNA. Total RNA was extracted from each 75-cm2 culture as above (5), and 5-10 ,ug were treated with 3 U of RNase-free DNase I (Boehringer Manheim) for 30 min at 37TC. After phenol-chloroform extraction, 1-5 Mg of RNA were analyzed by RT-PCR following the manufacturer's protocol (RT-PCR Kit; Perkin-Elmer Cetus). Random hexamers and oligonucleotide FBlAS were used in the reverse-transcription reaction. To control for DNA contamination, the same amounts of this DNase-treated RNA were analyzed by PCR without prior reverse transcription. All products were electrophoresed through a 1% agarose gel and transferred to a nylon membrane using a Turboblotter apparatus as per the manufacturer's protocol (Schleicher & Schuell, Inc., Keene, NH). Using a previously described allele-specific oligonucleotide hybridization method (20) , the identity of the amplified cDNA was confirmed by hybridization with 32P-labeled oligonucleotide FBIS, which is complementary to sequence within FBN1 exon 1. For transcript quantification, RT-PCR was performed on DNase-treated total RNA that was extracted from representative mouse 3T3 transfected cell line E3. Random hexamers were used for reverse transcription. Each PCR reaction utilized sense and antisense primers that were exactly complementary to sequences in both mouse and human exons 1 and 3, respectively: ME1S-A and ME3AS-A; ME1S-A and ME3AS-B; ME1S-B and ME3AS-A. RT-PCR products were electrophoresed and Southern transferred as above and hybridized to radiolabeled oligonucleotide MElS-C, which is complementary to both endogenous and mini-gene-derived transcripts, or oligonucleotide FB1CS, which is complementary only to the mini-gene transcript. Quantification was performed as previously described (17) .
Immunohistochemistry. Single wells of a four-chamber slide (LabTek; Nunc, Naperville, IL) were seeded with 2 x 105 cells from each clonal culture and grown in neomycin-containing medium for 72 h. The cells were rinsed with PBS and soaked in -20°C acetone for 10 min. The acetone was then replaced with fresh, room temperature PBS for 15 min. The PBS was removed, and the primary antibody (anti-fibrillin monoclonal 69, kindly provided by Dr. Lynn Sakai, Portland Shriners Hospital, Portland, Oregon) was added at 1:150 dilution in PBS. The antibody was incubated for 3 h at room temperature. The cells were then washed three times for 3 min each in PBS. The secondary antibody (HITC-conjugated anti-mouse IgG; Sigma Chem. Co., St. Louis, MO) at 1:256 dilution in PBS was then added to the cells for 30 min at room temperature. The cells were washed again three times for 3 min each in PBS, then stained for 5 min in 1 jug/ml propidium iodide (Sigma), and put through a final series of four 3-min PBS washes. The slides were fixed in mounting medium (Cytoseal 280; Stephens Scientific, Riverdale, NJ) and examined by fluorescent microscopy with a 450-490-nm filter. Immunofluorescence was also performed on all cultures with a monoclonal antibody to fibronectin (Sigma), an extracellular matrix protein which is unaffected in MFS, to control for specificity.
Assessing presence of secreted polypeptide. Cells harboring the mini-gene construct as well as control cells harboring only the parent pcDNA3 vector were grown in chamber slides as described above but in cell culture medium without neomycin. After 24 h, 1 ml of the medium from atop these cells was used to resuspend 2 X 105 normal, untransfected fibroblasts which had been pelleted by centrifugation. These cells were then plated in chamber slides and carried through the immunohistochemical procedure described above. If the mutant polypeptide were secreted into the medium of pDEL2-transfected cells, it would be expected to disrupt microfibrillogenesis.
Pulse-chase analysis. (Fig. 3 B) . On average, the contribution of pDEL2-derived transcript is -140% of that from the endogenous alleles. This represents an overestimate as the smaller, mini-gene-derived product would be preferentially amplified in a PCR-based assay. Nevertheless, these data suggest that the mutant mini-gene product is not grossly overproduced in this model system relative to the in vivo situation in patients with the Marfan syndrome.
Immunohistochemistry. Shown in Fig. 4 ( 16) . Taken together, these data suggest that mutant fibrillin monomer has the ability to impair matrix utilization of wild-type fibrillin but that the mutant protein has a diminished or absent capacity to interact with wild-type monomers that have already incorporated into microfibrils.
Pulse-chase analysis. Polyacrylamide electrophoresis gels of cellular protein extracts after 35S-cysteine pulse and unlabeled-cysteine chase were evaluated by autoradiography and scanning densitometry as previously described (15) . Calculated levels of fibrillin synthesis and deposition are presented in Table  II . As would be expected from cells expressing two normal fibrillin alleles, -100% synthesis of fibrillin is observed in all of the pDEL2-transfected cell lines. Matrix deposition, however, is greatly reduced in these lines, to 50% or less of that seen in control lines. Data obtained from cells of patient MS-8 are presented for reference ( 16) . In these cells with one wildtype fibrillin allele, -50% fibrillin synthesis is observed, as expected.
These data suggest that expression of this mutant, truncated fibrillin polypeptide, even on a background of two wild-type fibrillin alleles, is sufficient to disrupt normal fibrillin aggregation and reproduce the MFS cellular phenotype.
Discussion
The hypothesis that MFS follows a dominant-negative mechanism of pathogenesis has been borne from several observations. The disease is inherited in an autosomal dominant fashion and is caused by mutations in fibrillin, a matrix protein known to multimerize. The severe deficiency of extracellular fibrillin, which is characteristic of classic MFS, is far below the amount predicted by a single functioning FBN1 allele. Lastly, very reduced levels of mutant transcript have been associated with extremely mild disease in patients. We now establish a dominant-negative effect in a cell culture model using a disease allele from a patient with severe MFS. We have shown that the presence of a 100-amino acid polypeptide from the aminoterminus of fibrillin and encoded by this patient's mutant allele (see Fig. 1 ) is sufficient to perturb normal fibrillin multimer assembly and reproduce the MFS cellular phenotype, even on a background of two normal FBN1 alleles. These data further support the conclusion that deficiency of wild-type fibrillin is not the sole determinant of pathology in MFS, but rather, that some adverse, dominant-negative interaction between mutant and wild-type fibrillin monomers is responsible for microfibrillar disruption and consequent disease.
Correlating genotype with phenotype in MFS is an active and ongoing effort by numerous investigators. Among the patterns that have emerged from such studies is the observation that FBN1 missense mutations are associated with classic and severe MFS whereas mutations that produce premature termination codons and low levels of mutant transcript are associated with a range of phenotypic severity (17) . The identification of one such mutation, a 4-bp insertion (5138insTTCA) found in a patient with extremely mild disease, served as a forerunner to the studies presented in this manuscript. This mutation produces a frameshift and consequent downstream premature termination codon. It has been well documented that premature Further insight has been gained from two other patients who harbored premature termination codon-producing mutations. Interestingly, mutant transcript levels in these individuals were 16 and 25%, and their disease presentation was classic and severe ( 17) . This observation of increased disease severity with increased mutant transcript level led us to augment the dominant-negative concept with the hypothesis that a threshold level of mutant transcript and therefore monomer, perhaps between 6 and 16%, may be necessary to produce classic and severe disease. An analogous threshold hypothesis has been suggested for another connective tissue disorder, osteogenesis imperfecta (24) . Again, the data presented in this manuscript are consistent with such a hypothesis. The (17, 26, 27) . Interestingly, the vast majority of FBN1 missense mutations in MFS patients occur within EGFlike domains and alter residues with putative significance for calcium binding (17, 28 A complete understanding of the pathogenesis of this disease is likely to be attained only through study of transgenic models that mimic the physiologic complexity of the human system. Ideally, an animal model of MFS should provide an experimental paradigm that is applicable to human physiology and that enables diagnostic and therapeutic intervention. It would therefore facilitate the development, evaluation, and refinement of medical and surgical therapies for MFS and thus allow advances to be directly relevant to the human condition. Our data suggest that expression of the human extreme 5' fibrillin-coding sequence may be sufficient, in isolation, to produce such a model. In this context, it should be noted that FBN1 is highly conserved across species. The porcine fibrillin cDNA, for example, has 92% sequence identity to human FBN1 and 98% identity and 99% homology at the amino acid level (Z. A. Eldadah and H. C. Dietz, unpublished data). This extreme conservation across the full 10-kb length of coding sequence suggests a functional significance to each of the individual domains within fibrillin. It also suggests that fibrillin monomers from one species may be able to interact with those of another. Indeed, in this study truncated human fibrillin polypeptides induced similar effects on human as well as murine microfibrils.
Ultimately, a principal objective of the fuller understanding of MFS gained though development of an animal model and other routes of investigation is relieving the clinical burden of patients. Toward this aim, verification of the dominant-negative nature of MFS pathogenesis now offers the possibility of mutant allele knockout as a potential strategy for gene therapy. Approaches based on antisense inhibition of mutant transcript expression, for example, may hold promise and can be tested in a cell culture system.
